HCRN GU14-188: Phase Ib/II study of neoadjuvant pembrolizumab and chemotherapy for T2-4aNOMO urothelial cancer.

被引：0

作者：

Brown, Jason

Kaimakliotis, Hristos Z.

Kelly, William Kevin

Ammons, Vikki

Picus, Joel

Walling, Radhika

Hashemi-Sadraei, Neda

Fu, Pingfu

Margevicius, Seunghee P.

Adra, Nabil

Garcia, Jorge A.

McKay, Rana R.

Hoimes, Christopher J.

机构：

[1] Univ Hosp Seidman Canc Ctr, Div Oncol, Cleveland, OH USA

[2] Indiana Univ, Simon Canc Ctr, Indianapolis, IN 46204 USA

[3] Thomas Jefferson Univ, Dept Med Oncol & Urol, Sidney Kimmel Med Coll, Philadelphia, PA 19107 USA

[4] Virginia Oncol Associates, Norfolk, VA USA

[5] Washington Univ, Sch Med, Div Med Oncol, St Louis, MO USA

[6] Community Hosp Oncol Phys, Indianapolis, IN USA

[7] Univ New Mexico, Comprehens Canc Ctr, Albuquerque, NM 87131 USA

[8] Case Western Reserve Univ, Cleveland, OH 44106 USA

[9] Case Western Reserve Univ, Sch Med, Cleveland, OH USA

[10] Indiana Univ, Simon Comprehens Canc Ctr, Indianapolis, IN 46204 USA

[11] Univ Hosp Seidman Canc Ctr, Cleveland, OH USA

[12] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA

[13] Duke Univ, Duke Canc Inst, Durham, NC USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

448

引用

页数：1

共 39 条

[1] HCRN GU14-188: Neoadjuvant pembrolizumab (P) and gemcitabine (G) with or without cisplatin (C) in muscle invasive urothelial cancer (MIUC)
Hoimest, Christopher J.
Abouassaly, Robert
Saltzman, Joel N.
Fleming, Mark T.
Hoffman-Censits, Jean H.
Byrd, Tara
Eitman, Cheryl
Snyder-Willis, Michele
O'Neill, Jodi
Wood, Lisa
Elliott, Robin
Cooney, Matthew M.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[2] Phase Ib/II neoadjuvant (N-) pembrolizumab (P) and chemotherapy for locally advanced urothelial cancer (laUC): Final results from the cisplatin (C)- eligible cohort of HCRN GU14-188.
Hoimes, Christopher J.
Adra, Nabil
Fleming, Mark T.
Kaimakliotis, Hristos Z.
Picus, Joel
Smith, Zachary L.
Walling, Radhika
Trabulsi, Edouard John
Hoffman-Censits, Jean H.
Koch, Michael O.
Cary, Clint
Abouassaly, Robert
Eitman, Cheryl
Fu, Pingfu
Goolamier, Gordon
Calaway, Adam C.
Ponsky, Lee Evan
Kelly, William Kevin
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[3] A phase Ib/II study of neoadjuvant pembrolizumab (pembro) and chemotherapy for locally advanced urothelial cancer (UC)
Hoimes, C. J.
Albany, C.
Hoffman-Censits, J.
Fleming, M. T.
Trabulsi, E.
Picus, J.
Cary, C.
Koch, M. O.
Walling, R.
Kelly, W.
Godwin, J. L.
Cooney, M.
Fu, P.
Nelson, A.
Patel, K.
Eitman, C.
Breen, T.
Neal, A.
Kaimakliotis, H.
ANNALS OF ONCOLOGY, 2018, 29 : 726 - 726
[4] Randomized double-blind phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients (pts) with metastatic urothelial cancer (mUC): HCRN GU14-182.
Galsky, Matt D.
Pal, Sumanta K.
Mortazavi, Amir
Milowsky, Matthew I.
George, Saby
Gupta, Sumati
Fleming, Mark T.
Dang, Long H.
Geynisman, Daniel M.
Walling, Radhika
Alter, Robert S.
Robin, Erwin L.
Wang, Jue
Gupta, Shilpa
Chism, David D.
Picus, Joel
Philips, George
Quinn, David I.
Hahn, Noah M.
Yu, Menggang
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[5] Phase II neoadjuvant (N-) gemcitabine (G) and pembrolizumab (P) for locally advanced urothelial cancer (laUC): Interim results from the cisplatin (C)-ineligible cohort of GU14-188.
Kaimakliotis, Hristos Z.
Adra, Nabil
Kelly, William Kevin
Trabulsi, Edouard John
Lauer, Richard C.
Picus, Joel
Smith, Zachary L.
Walling, Radhika
Masterson, Timothy A.
Calaway, Adam C.
Koch, Michael O.
Sonderman, Elizabeth
Fu, Pingfu
Goolamier, Gordon
Eitman, Cheryl
Ponsky, Lee Evan
Hoimes, Christopher J.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[6] A MULTICENTER PHASE 1B/2 STUDY OF NEOADJUVANT PEMBROLIZUMAB AND CISPLATIN CHEMOTHERAPY FOR MUSCLE INVASIVE UROTHELIAL CANCER
Kaimakliotis, Hristos
Albany, Costantine
Hoffman-Censits, Jean
Trabulsi, Edouard
Kelly, W. Kevin
Picus, Joel
Adra, Nabil
Cary, Clint
Koch, Michael
Fleming, Mark
Walling, Radhika
Godwin, J. Luke
Abouassaly, Robert
Cooney, Matthew
Fu, Pingfu
Nelson, Ariel
Xavier, Ginu
Ponsky, Lee
Hoimes, Christopher
JOURNAL OF UROLOGY, 2019, 201 (04): : E924 - E925
[7] Combination checkpoint immunotherapy and cytotoxic chemotherapy: Further results from a phase Ib/II trial of pembrolizumab and docetaxel or gemcitabine in patients with advanced or metastatic urothelial cancer.
Parikh, Mamta
Pan, Chong-Xian
Beckett, Laurel
Li, Yueju
Robles, Daniel
DeVisser, Christina
Lara, Primo
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
[8] Randomized multicenter phase Ib/II study of neoadjuvant chemoradiation therapy (CRT) alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic cancer.
Rahma, Osama E.
Katz, Matthew H. G.
Wolpin, Brian M.
Dias-Costa, Andressa
Nowak, Jonathan
Rodig, Scott J.
Dougan, Stephanie
Bekaii-Saab, Tanios S.
Stucky, Chee-Chee H.
Elias, Rawad
Petroni, Gina R.
Bauer, Todd W.
Slingluff, Craig L.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[9] A multi-center, single-arm, phase Ib study of pembrolizumab (MK-3475) in combination with chemotherapy for patients with advanced colorectal cancer: HCRN GI14-186
Herting, Cameron J.
Farren, Matthew R.
Tong, Yan
Liu, Ziyue
O'Neil, Bert
Bekaii-Saab, Tanios
Noonan, Anne
McQuinn, Christopher
Mace, Thomas A.
Shaib, Walid
Wu, Christina
El-Rayes, Bassel F.
Shahda, Safi
Lesinski, Gregory B.
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021, 70 (11) : 3337 - 3348
[10] A multi-center, single-arm, phase Ib study of pembrolizumab (MK-3475) in combination with chemotherapy for patients with advanced colorectal cancer: HCRN GI14-186
Cameron J. Herting
Matthew R. Farren
Yan Tong
Ziyue Liu
Bert O’Neil
Tanios Bekaii-Saab
Anne Noonan
Christopher McQuinn
Thomas A. Mace
Walid Shaib
Christina Wu
Bassel F. El-Rayes
Safi Shahda
Gregory B. Lesinski
Cancer Immunology, Immunotherapy, 2021, 70 : 3337 - 3348

← 1 2 3 4 →